Bayer offers deep-value recovery upside if glyphosate litigation is contained, but its equity remains a legal binary play burdened by Monsanto liabilities, high debt, and near-term negative free cash flow.
Overview
Bayer is a global life-sciences conglomerate spanning Crop Science, Pharmaceuticals, and Consumer Health. Its core franchises serve essential needs in food security, chronic disease treatment, oncology, renal care, diagnostics, and self-care. The business has strong competitive assets—seeds and traits, global pharmaceutical brands, FieldView digital agriculture, and legacy OTC trust—but remains defined by the tension between durable operating value and severe Monsanto-related legal, debt, and cash-flow overhangs.